Table 3 Positive telehealth satisfaction according to demographic and patient-specific factors
From: Evaluation of pediatric rheumatology telehealth satisfaction during the COVID-19 pandemic
Variable | Total Score | Usefulness | Ease of Use | Effectiveness | Satisfaction/ Future Use |
|---|---|---|---|---|---|
Age | |||||
0–5 years | 83% | 65% | 90% | 90% | 85% |
6–12 years | 83% | 73% | 87% | 87% | 86% |
13–17 years | 82% | 76% | 86% | 85% | 80% |
18+ years | 73% | 69% | 75% | 76% | 70% |
Race | |||||
Caucasian | 81% | 73% | 86% | 84% | 81% |
African American | 88% | 77% | 90% | 97% | 88% |
Asian | 85% | 79% | 86% | 90% | 84% |
Other | 77% | 62% | 84% | 86% | 76% |
Conditiona | |||||
JIA | 79% | 68% | 85% | 84% | 80% |
SLE | 85% | 81% | 88% | 88% | 83% |
Inflammatory diseaseb | 82% | 73% | 89% | 84% | 82% |
AMPS | 79% | 76% | 78% | 83% | 78% |
Other/Unknown | 83% | 74% | 88% | 89% | 82% |
Time since diagnosis | |||||
Within 6 months | 84% | 76% | 89% | 86% | 84% |
Greater than 6 months | 81% | 72% | 85% | 85% | 80% |
Prescribed rheumatologic medication(s) | |||||
Yes (n = 148) | 82% | 73% | 87% | 87% | 82% |
Glucocorticoid therapy | 82% | 75% | 88% | 84% | 81% |
No glucocorticoid therapy | 83% | 73% | 87% | 87% | 83% |
No | 80% | 72% | 84% | 84% | 79% |
Rheumatology visit type (n = 212) | |||||
New | 80% | 70% | 86% | 86% | 79% |
Established | 80% | 72% | 83% | 84% | 80% |